Cargando…
Is Chimeric Antigen Receptor T-cell Therapy the Future of Autoimmunity Management?
Clinical trials with chimeric antigen receptor (CAR) T-cell therapy in oncology have been promising. The spectrum of this novel therapy is being expanded to include autoimmunity. It ensures “targeted treatment,” resulting in more selective outcomes, fewer toxic effects, and a permanent restoration o...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cureus
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279003/ https://www.ncbi.nlm.nih.gov/pubmed/30533341 http://dx.doi.org/10.7759/cureus.3407 |